Application of a High Throughput Method of Biomarker Discovery to Improvement of the EarlyCDT(®)-Lung Test

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Dec 29

PMID 23272083

Citations 13

Authors

Isabel K Macdonald

Andrea Murray

Graham F Healey

Celine B Parsy-Kowalska

Jared Allen

Jane McElveen

Chris Robertson

Herbert F Sewell

Caroline J Chapman

John F R Robertson

Affiliations

Soon will be listed here.

Abstract

Background: The National Lung Screening Trial showed that CT screening for lung cancer led to a 20% reduction in mortality. However, CT screening has a number of disadvantages including low specificity. A validated autoantibody assay is available commercially (EarlyCDT®-Lung) to aid in the early detection of lung cancer and risk stratification in patients with pulmonary nodules detected by CT. Recent advances in high throughput (HTP) cloning and expression methods have been developed into a discovery pipeline to identify biomarkers that detect autoantibodies. The aim of this study was to demonstrate the successful clinical application of this strategy to add to the EarlyCDT-Lung panel in order to improve its sensitivity and specificity (and hence positive predictive value, (PPV)).

Methods And Findings: Serum from two matched independent cohorts of lung cancer patients were used (n = 100 and n = 165). Sixty nine proteins were initially screened on an abridged HTP version of the autoantibody ELISA using protein prepared on small scale by a HTP expression and purification screen. Promising leads were produced in shake flask culture and tested on the full assay. These results were analyzed in combination with those from the EarlyCDT-Lung panel in order to provide a set of re-optimized cut-offs. Five proteins that still displayed cancer/normal differentiation were tested for reproducibility and validation on a second batch of protein and a separate patient cohort. Addition of these proteins resulted in an improvement in the sensitivity and specificity of the test from 38% and 86% to 49% and 93% respectively (PPV improvement from 1 in 16 to 1 in 7).

Conclusion: This is a practical example of the value of investing resources to develop a HTP technology. Such technology may lead to improvement in the clinical utility of the EarlyCDT--Lung test, and so further aid the early detection of lung cancer.

Citing Articles

Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.

Sullivan F, Mair F, Anderson W, Chew C, Dorward A, Haughney J PLoS One. 2025; 20(1):e0306163.

PMID: 39774508 PMC: 11709295. DOI: 10.1371/journal.pone.0306163.

Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.

Feng X, Wu W, Onwuka J, Haider Z, Alcala K, Smith-Byrne K J Natl Cancer Inst. 2023; 115(9):1050-1059.

PMID: 37260165 PMC: 10483263. DOI: 10.1093/jnci/djad071.

EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.

Duarte A, Corbett M, Melton H, Harden M, Palmer S, Soares M Health Technol Assess. 2022; 26(49):1-184.

PMID: 36534989 PMC: 9791464. DOI: 10.3310/IJFM4802.

A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker.

Toumazis I, Erdogan S, Bastani M, Leung A, Plevritis S JNCI Cancer Spectr. 2021; 5(6).

PMID: 34738073 PMC: 8564700. DOI: 10.1093/jncics/pkab081.

Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues.

de Jonge H, Iamele L, Maggi M, Pessino G, Scotti C Cancers (Basel). 2021; 13(4).

PMID: 33672007 PMC: 7919283. DOI: 10.3390/cancers13040813.

References

Ingvarsson S . The myc gene family proteins and their role in transformation and differentiation. Semin Cancer Biol. 1990; 1(6):359-69. View

Murray A, Chapman C, Healey G, Peek L, Parsons G, Baldwin D . Technical validation of an autoantibody test for lung cancer. Ann Oncol. 2010; 21(8):1687-1693. PMC: 2911202. DOI: 10.1093/annonc/mdp606. View

Aslanidis C, de Jong P . Ligation-independent cloning of PCR products (LIC-PCR). Nucleic Acids Res. 1990; 18(20):6069-74. PMC: 332407. DOI: 10.1093/nar/18.20.6069. View

Parsy C, Chapman C, Barnes A, Robertson J, Murray A . Two-step method to isolate target recombinant protein from co-purified bacterial contaminant SlyD after immobilised metal affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 853(1-2):314-9. DOI: 10.1016/j.jchromb.2007.03.046. View

Lee K, Chung H, Kim H, Oh S, Ha M, Baik J . Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease. Arthritis Rheum. 2003; 48(7):2025-35. DOI: 10.1002/art.11074. View

Moriya T, Kasajima A, Ishida K, Kariya Y, Akahira J, Endoh M . New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol. 2006; 39(1):8-13. DOI: 10.1007/s00795-006-0309-8. View

Nahm D, Lee K, Shin J, Ye Y, Kang Y, Park H . Identification of alpha-enolase as an autoantigen associated with severe asthma. J Allergy Clin Immunol. 2006; 118(2):376-81. DOI: 10.1016/j.jaci.2006.04.002. View

Krause P, Tureci O, Micke P, Buhl R, Huber C, Sahin U . SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. J Immunol Methods. 2003; 283(1-2):261-7. DOI: 10.1016/j.jim.2003.09.014. View

Yoneda M, Fujii A, Ito A, Yokoyama H, Nakagawa H, Kuriyama M . High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto's encephalopathy. J Neuroimmunol. 2007; 185(1-2):195-200. DOI: 10.1016/j.jneuroim.2007.01.018. View

10.

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

11.

Nau M, Brooks B, Battey J, Sausville E, Gazdar A, Kirsch I . L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985; 318(6041):69-73. DOI: 10.1038/318069a0. View

12.

Macdonald I, Allen J, Murray A, Parsy-Kowalska C, Healey G, Chapman C . Development and validation of a high throughput system for discovery of antigens for autoantibody detection. PLoS One. 2012; 7(7):e40759. PMC: 3399887. DOI: 10.1371/journal.pone.0040759. View

13.

Chapman C, Healey G, Murray A, Boyle P, Robertson C, Peek L . EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 2012; 33(5):1319-26. PMC: 3460172. DOI: 10.1007/s13277-012-0379-2. View

14.

Swensen S, Jett J, Hartman T, Midthun D, Mandrekar S, Hillman S . CT screening for lung cancer: five-year prospective experience. Radiology. 2005; 235(1):259-65. DOI: 10.1148/radiol.2351041662. View

15.

Canelle L, Bousquet J, Pionneau C, Deneux L, Imam-Sghiouar N, Caron M . An efficient proteomics-based approach for the screening of autoantibodies. J Immunol Methods. 2005; 299(1-2):77-89. DOI: 10.1016/j.jim.2005.01.015. View

16.

Moll R, Lowe A, Laufer J, Franke W . Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992; 140(2):427-47. PMC: 1886432. View

17.

Moll R, Schiller D, Franke W . Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990; 111(2):567-80. PMC: 2116178. DOI: 10.1083/jcb.111.2.567. View

18.

Boyle P, Chapman C, Holdenrieder S, Murray A, Robertson C, Wood W . Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2010; 22(2):383-9. PMC: 3030465. DOI: 10.1093/annonc/mdq361. View

19.

Desmetz C, Mange A, Maudelonde T, Solassol J . Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med. 2011; 15(10):2013-24. PMC: 4394213. DOI: 10.1111/j.1582-4934.2011.01355.x. View

20.

Baldwin R . Tumour-specific immunity against spontaneous rat tumours. Int J Cancer. 1966; 1(3):257-64. DOI: 10.1002/ijc.2910010305. View